Grifols SA, Barcelona (GRFS) Downgraded to “Hold” at Zacks Investment Research

Grifols SA, Barcelona (NASDAQ:GRFS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Saturday.

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

How to Become a New Pot Stock Millionaire

A number of other brokerages have also recently commented on GRFS. BidaskClub raised Grifols SA, Barcelona from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. ValuEngine upgraded Grifols SA, Barcelona from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. UBS lowered Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research note on Friday, November 24th. Morgan Stanley cut their price target on Grifols SA, Barcelona from $23.00 to $22.00 and set an “underweight” rating for the company in a research note on Thursday, March 1st. Finally, HSBC upgraded Grifols SA, Barcelona from a “reduce” rating to a “hold” rating in a research note on Wednesday, March 14th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. Grifols SA, Barcelona has a consensus rating of “Hold” and a consensus target price of $22.50.

GRFS stock opened at $20.37 on Friday. Grifols SA, Barcelona has a twelve month low of $17.99 and a twelve month high of $25.18. The company has a market capitalization of $14,298.31, a price-to-earnings ratio of 21.90, a P/E/G ratio of 1.33 and a beta of 1.18. The company has a quick ratio of 1.35, a current ratio of 3.01 and a debt-to-equity ratio of 1.62.

A number of hedge funds have recently modified their holdings of GRFS. BNP Paribas Arbitrage SA increased its stake in Grifols SA, Barcelona by 7.9% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 31,440 shares of the biotechnology company’s stock worth $688,000 after buying an additional 2,300 shares in the last quarter. New York State Common Retirement Fund increased its stake in Grifols SA, Barcelona by 3.4% in the 3rd quarter. New York State Common Retirement Fund now owns 1,133,205 shares of the biotechnology company’s stock worth $24,806,000 after buying an additional 37,157 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Grifols SA, Barcelona by 8.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,054,762 shares of the biotechnology company’s stock worth $44,958,000 after buying an additional 153,563 shares in the last quarter. Van ECK Associates Corp increased its stake in Grifols SA, Barcelona by 11.8% in the 3rd quarter. Van ECK Associates Corp now owns 917,676 shares of the biotechnology company’s stock worth $20,088,000 after buying an additional 96,869 shares in the last quarter. Finally, Morningstar Investment Services LLC increased its stake in Grifols SA, Barcelona by 15.5% in the 3rd quarter. Morningstar Investment Services LLC now owns 16,537 shares of the biotechnology company’s stock worth $362,000 after buying an additional 2,216 shares in the last quarter. Institutional investors and hedge funds own 22.26% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Grifols SA, Barcelona (GRFS) Downgraded to “Hold” at Zacks Investment Research” was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3294506/grifols-sa-barcelona-grfs-downgraded-to-hold-at-zacks-investment-research.html.

Grifols SA, Barcelona Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Get a free copy of the Zacks research report on Grifols SA, Barcelona (GRFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Grifols SA, Barcelona (NASDAQ:GRFS)

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Novartis  Shares Gap Down to $81.70
Novartis Shares Gap Down to $81.70
Northern Oil and Gas  Bonds Rise 5.5% During Trading
Northern Oil and Gas Bonds Rise 5.5% During Trading
Post  Bonds Trading 1.8% Lower
Post Bonds Trading 1.8% Lower
Analyzing Dicks Sporting Goods  and Barnes & Noble Education
Analyzing Dicks Sporting Goods and Barnes & Noble Education
FuckToken Price Reaches $0.0166 on Major Exchanges
FuckToken Price Reaches $0.0166 on Major Exchanges
Quantum  versus Western Digital  Financial Survey
Quantum versus Western Digital Financial Survey


© 2006-2018 Ticker Report. Google+.